American Portfolios Advisors Atea Pharmaceuticals, Inc. Transaction History

American Portfolios Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Mar 21, 2023	BUY	$5.5 - $9.19 $550 - $919	100 New	100 $722,000
Q4 2021 Mar 21, 2023	BUY	$7.67 - $44.59 $767 - $4,459	100 New	100 $894,000
Q3 2021 Mar 22, 2023	BUY	$21.33 - $35.06 $2,133 - $3,506	100 New	100 $3.51 Million
Q2 2021 Mar 22, 2023	BUY	$19.22 - $59.08 $1,922 - $5,908	100 New	100 $2.15 Million
Q1 2021 Mar 22, 2023	BUY	$41.42 - $88.44 $4,142 - $8,844	100 New	100 $6.18 Million
Q4 2020 Mar 22, 2023	BUY	$26.36 - $41.78 $5,403 - $8,564	205 New	205 $8.57 Million

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $275M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

Stay updated on American Portfolios Advisors with notifications on news.